news
Outsourcing facility opens highly potent compound manufacturing suite
The development of a highly potent active pharmaceutical ingredient (HPAPI) contract manufacturing facility has been completed in the US.
List view / Grid view
Contract Manufacturing
news
Few CMOs equipped to manufacture cell and gene therapies, finds study
A report has said that with only 152 CMOs able to manufacture the 7,000 cell and gene therapies in the pipeline, production bottlenecks may occur.
news
Indian CMO market hotbed for private equity investment, says report
A report suggests that India’s CMO market has recently attracted investment from global private equity firms due to favourable government policies.
article
Outsourcing update: the latest developments in pharma
European Pharmaceutical Review explores some of the latest developments in outsourcing, including clinical development and production agreements; acquisitions and collaborations; and expansions.
news
Emergent to assist in production of US COVID-19 vaccine candidates
The company announces it has been task ordered by BARDA to assist in the US government’s efforts to deliver COVID-19 vaccines.
news
CDMO delivers 4,000 doses of COVID-19 vaccine candidate for Phase II/III trial
Advent announced it has manufactured and delivered the first 4,000 doses of the AZD1222 vaccine candidate for the University of Oxford clinical trial.
news
Report reveals CMOs in Italy concentrated in worst-hit COVID-19 regions
According to findings, the majority of CMOs in Italy are found in the locations hit worst by COVID-19, meaning the pharma supply chain has been greatly impacted.
article
The opportunities for CDMOs in the pharmaceutical industry
A PricewaterhouseCoopers report has highlighted the directions that the growth of the contract development and manufacturing organisation (CDMO) outsourcing market will take in the near future.
news
CDMO pledges increased production of hydroxychloroquine sulfate, potential COVID-19 treatment
The CDMO AMRI has said it will boost its production of the malaria drug hydroxychloroquine sulfate, identified as a potential COVID-19 treatment, following an emergency use authorisation from the FDA.
news
CDMO recognised in six outsourcing award categories
A Contract Development and Manufacturing Organisation (CDMO) has been recognised in six different categories at the 2020 CMO Leadership Awards.
news
Gilead aims to produce one million remdesivir treatment courses by 2021
A letter from the CEO of Gilead reveals how the company plans to scale up production of remdesivir in light of the COVID-19 pandemic.
article
COVID-19 update: coronavirus and the pharmaceutical supply chain
With concerns rising about medicine availability during the global COVID-19 coronavirus pandemic, European Pharmaceutical Review explores how the pharmaceutical supply chain is faring.
news
Big pharma’s in-house manufacturing impacted by COVID-19 outbreak in China
According to an outlet, the in-house manufacturing of biopharma products has been threatened by the COVID-19 outbreak, especially in China.
news
FDA announces changes that will soon affect compounders
A change to the law will soon be impacting compounding of certain products beginning on 23 March 2020 the US Food and Drug Administration (FDA) has announced.
article
Trends in the CDMO industry for 2020
Over the past decade, the pharmaceutical industry has witnessed rapid growth in outsourcing services, driven by various factors including the growth of small molecules, increasing API complexities and the need to optimise costs. Here, Peter DeYoung shares his thoughts on the key trends he expects to see in the contract…
